A Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) for the Treatment of Chronic Renal Anemia in Participants With Diabetic Nephropathy
Launched by HOFFMANN-LA ROCHE · Aug 30, 2010
Trial Information
Current as of September 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diabetic nephropathy
- • Chronic renal anemia with stage III-IV CKD
- • Not on dialysis and not expected to require dialysis within the next 6 months
- • Not receiving any ESA in the 2 months prior to study
- • Adequate iron status
- Exclusion Criteria:
- • Transfusion of red blood cells during the previous 2 months
- • Known or clinical suspicion of pure red cell aplasia
- • Hypersensitivity to recombinant human erythropoietin, polyethylene glycol or to any constituent of the study medication
- • Haemoglobinopathy
- • Significant acute or chronic bleeding
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Delhi, Delhi, India
Hyderabad, Andhra Pradesh, India
New Delhi, Delhi, India
Ahmedabad, , India
Bangalore, , India
Delhi, , India
Delhi, , India
Hyderabad, , India
Kolkata, , India
Mumbai, , India
Mumbai, , India
Mumbai, , India
Pune, , India
Pune, , India
Patients applied
Trial Officials
Clinical Trials
Study Director
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials